199666-03-0
199666-03-0
Chemical Structure
Ro 61-8048
- CAS No.: 199666-03-0
- Formula:C17H15N3O6S2
- Molecular Weight:421.45
IUPAC Name: 3,4-dimethoxy-N-(4-(3-nitrophenyl)thiazol-2-yl)benzenesulfonamide
InChIKey: NDPBMCKQJOZAQX-UHFFFAOYSA-N
SMILES: O=S(C1=CC=C(OC)C(OC)=C1)(NC2=NC(C3=CC=CC([N+]([O-])=O)=C3)=CS2)=O
Biological Activity: Ro 61-8048 is an orally active and selective inhibitor of kynurenine 3-hydroxylase, with an IC50 of 37 nM. Ro 61-8048 provokes a significant increase of extracellular kynurenic acid concentrations[1].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Ro 61-8048 | 99.93% | Ro 61-8048 is an orally active and selective inhibitor of kynurenine 3-hydroxylase, with an IC50 of 37 nM. Ro 61-8048 provokes a significant increase of extracellular kynurenic acid concentrations. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Ro 61-8048 (Standard) | ≥98% | Ro 61-8048 (Standard) is the analytical standard of Ro 61-8048. This product is intended for research and analytical applications. Ro 61-8048 is an orally active and selective inhibitor of kynurenine 3-hydroxylase, with an IC50 of 37 nM. Ro 61-8048 provokes a significant increase of extracellular kynurenic acid concentrations. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Anticancer agent 37 | Anticancer agent 37 (compound 18), a sulfonylurea derivative, is a potent anticancer agent. Anticancer agent 37 inhibits HePG2 cell growth with an IC50 of 17.2 µg/mL. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
CAY10698 | 99.28% | CAY10698 (compound 1) is a potent and selective inhibitor of 12-Lipoxygenase (12-LOX) with an IC50 of 5.1 μM. CAY10698 is inactive against 5-LOX, 15-LOX-1, 15-LOX-2 and COX-1/2. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
OX11 | OX11 is a selective inhibitor of S. pneumoniae, P. aeruginosa, and E. coli bacterial strains. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
BMS-986121 | 99.96% | BMS-986121 is a positive allosteric modulator (PAM) of the μ opioid receptor extracted from patent WO2014107344. BMS-986121 is built on a chemical scaffold representing a new chemotype for μ receptor PAMs. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
BAZ1A-IN-1 | 99.91% | BAZ1A-IN-1 is a potent inhibitor of BAZ1A (bromodomain-containing protein). BAZ1A-IN-1 shows a KD value of 0.52 μM against BAZ1A bromodomain. BAZ1A-IN-1 shows good anti-viability activity against cancer cell lines expressing a high level of BAZ1A, but weak or no activity against cancer cells with a low expression level of BAZ1A. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
CK2α-IN-1 | 98.34% | CK2α-IN-1 (compound 2) is a selective CK2α inhibitor (IC50=7.0 µM; Ki=1.6 µM) that exhibits a non-ATP-competitive mode of action. CK2α-IN-1 exhibits good potential for anticancer studies. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
PHGDH-IN-3 | 99.34% | PHGDH-IN-3 is an orally active phosphoglycerate dehydrogenase (PHGDH) inhibitor. PHGDH-IN-3 inhibits PHGDH with an IC50 value of 2.8 μM. PHGDH-IN-3 can be used for the research of cancer. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
JM6 | JM6 is a weak kynurenine 3-monooxygenase (KMO) inhibitor with an IC50 of 19.85 μM for mouse KMO. JM6 can be used for Alzheimer's diseases research. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
LM9 | LM9 is a potent, orally active MyD88 inhibitor. LM9 blocks TLR4/MyD88 binding, MyD88 homodimer formation, and TLR4/MyD88/NF-κB signaling pathway activation. LM9 prevents atherosclerosis by regulating inflammatory responses and oxidative stress in macrophages. LM9 efficiently mitigates inflammatory responses and fibrosis in obesity-induced cardiomyopathy. LM9 can be used for fibrosis and atherosclerosis research. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
MLS001006105 | 96.81% | MLS001006105 (ZINC13684400) is a GPR65 allosteric agonist. MLS001006105 displays GPR65 allosteric agonist activity at pH 8.40 but not at lower pH. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
